Table of Contents Author Guidelines Submit a Manuscript
Journal of Drug Delivery
Volume 2011 (2011), Article ID 160515, 9 pages
http://dx.doi.org/10.1155/2011/160515
Research Article

Liposomal Tumor Targeting in Drug Delivery Utilizing MMP-2- and MMP-9-Binding Ligands

1Department of Radiology, Sloan Kettering Institute for Cancer Research, 1275 York Ave., New York, NY 10065, USA
2Division of Pharmaceutical Technology, University of Helsinki, P.O. Box 56, FI-00014, Finland
3CTT Cancer Targeting Technologies Ltd., Viikinkaari 4 C, FI-00790 Helsinki, Finland
4Department of Food and Environmental Sciences, University of Helsinki, P.O. Box 56, FI-00014, Finland
5International Comprehensive Cancer Center Docrates, Saukonpaadenranta 2, FI-00180 Helsinki, Finland

Received 2 August 2010; Revised 20 October 2010; Accepted 19 November 2010

Academic Editor: Sophia Antimisiaris

Copyright © 2011 Oula Penate Medina et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. V. Torchilin and V. Weissig , Liposomes: A Practical Approach, Oxford University Press, Oxford, UK, 2nd edition, 2003.
  2. G. Bendas, “Immunoliposomes: a promising approach to targeting cancer therapy,” BioDrugs, vol. 15, no. 4, pp. 215–224, 2001. View at Google Scholar · View at Scopus
  3. H. Nagaset and J. F. Woessner Jr., “Matrix metalloproteinases. Minireview,” The Journal of Biological Chemistry, vol. 274, no. 31, pp. 21491–21494, 1999. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Curran and G. I. Murray, “Matrix metalloproteinasesmolecular aspects of their roles in tumour invasion and metastasis,” European Journal of Cancer, vol. 36, no. 13, pp. 1621–1630, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. L. J. McCawley and L. M. Matrisian, “Matrix metalloproteinases: they're not just for matrix anymore!,” Current Opinion in Cell Biology, vol. 13, no. 5, pp. 534–540, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. B. Schmalfeldt, D. Prechtel, K. Härting et al., “Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer,” Clinical Cancer Research, vol. 7, no. 8, pp. 2396–2404, 2001. View at Google Scholar · View at Scopus
  7. X. Wu, H. Li, L. Kang, L. Li, W. Wang, and B. Shan, “Activated matrix metalloproteinase-2 - A potential marker of prognosis for epithelial ovarian cancer,” Gynecologic Oncology, vol. 84, no. 1, pp. 126–134, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Ozalp, H. M. Tanir, O. T. Yalcin, S. Kabukcuoglu, U. Oner, and M. Uray, “Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors,” European Journal of Gynaecological Oncology, vol. 24, no. 5, pp. 417–420, 2003. View at Google Scholar · View at Scopus
  9. P. L. Torng, T. L. Mao, W. Y. Chan, S. C. Huang, and C. T. Lin, “Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression,” Gynecologic Oncology, vol. 92, no. 2, pp. 559–567, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Lopata, F. Agresta, M. A. Quinn, C. Smith, A. G. Ostor, and L. A. Salamonsen, “Detection of endometrial cancer by determination of matrix metalloproteinases in the uterine cavity,” Gynecologic Oncology, vol. 90, no. 2, pp. 318–324, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Davidson, I. Goldberg, J. Kopolovic et al., “MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma—a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization,” Gynecologic Oncology, vol. 73, no. 3, pp. 372–382, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. A. Talvensaari-Mattila, P. Pääkkö, and T. Turpeenniemi-Hujanen, “Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma,” British Journal of Cancer, vol. 89, no. 7, pp. 1270–1275, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. S. M. Ranuncolo, E. Armanasco, C. Cresta, E. B. De Kier Joffe, and L. Puricelli, “Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients,” International Journal of Cancer, vol. 106, no. 5, pp. 745–751, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Toth, D. C. Gervasi, and R. Fridman, “Phorbol ester-induced cell surface association of matrix metalloproteinase-9 in human MCF10A breast epithelial cells,” Cancer Research, vol. 57, no. 15, pp. 3159–3167, 1997. View at Google Scholar · View at Scopus
  15. P. C. Brooks, S. Silletti, T. L. von Schalscha, M. Friedlander, and D. A. Cheresh, “Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity,” Cell, vol. 92, no. 3, pp. 391–400, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. U. Jadhav, S. Chigurupati, S. S. Lakka, and S. Mohanam, “Inhibition of matrix metalloproteinase-9 reduces in vitro invasion and angiogenesis in human microvascular endothelial cells,” International Journal of Oncology, vol. 25, no. 5, pp. 1407–1414, 2004. View at Google Scholar · View at Scopus
  17. M. Nguyen, J. Arkell, and C. J. Jackson, “Human endothelial gelatinases and angiogenesis,” International Journal of Biochemistry and Cell Biology, vol. 33, no. 10, pp. 960–970, 2001. View at Publisher · View at Google Scholar · View at Scopus
  18. K. Komatsu, Y. Nakanishi, N. Nemoto, T. Hori, T. Sawada, and M. Kobayashi, “Expression and quantitative analysis of matrix metalloproteinase-2 and -9 in human gliomas,” Brain Tumor Pathology, vol. 21, no. 3, pp. 105–112, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Koivunen, W. Arap, H. Valtanen et al., “Cancer therapy with a novel tumor-targeting gelatinase inhibitor selected by phage peptide display,” Nature Biotechnology, vol. 17, pp. 768–774, 1999. View at Google Scholar
  20. O. Penate Medina, T. Söderlund, L. J. Laakkonen, E. K. J. Tuominen, E. Koivunen, and P. K. J. Kinnunen, “Binding of novel peptide inhibitors of type IV collagenases to phospholipid membranes and use in liposome targeting to tumor cells in vitro,” Cancer Research, vol. 61, no. 10, pp. 3978–3985, 2001. View at Google Scholar · View at Scopus
  21. O. Penate Medina, K. Kairemo, H. Valtanen et al., “Radionuclide imaging of tumor xenografts in mice using a gelatinase-targeting peptide,” Anticancer Research, vol. 25, no. 1, pp. 33–42, 2005. View at Google Scholar · View at Scopus
  22. O. P. Medina, Y. Zhu, and K. Kairamo, “Targeted liposomal drug delivery in cancer,” Current Pharmaceutical Design, vol. 10, no. 24, pp. 2981–2989, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Kanda, K. Inoue, S. Nojima et al., “Incorporation of ganglioside and spin-labelled ganglioside analogue into cell and liposome membranes,” The Journal of Biochemistry, vol. 91, pp. 2095–2098, 1982. View at Google Scholar
  24. P. S. Uster, T. M. Allen, B. E. Daniel, C. J. Mendez, M. S. Newman, and G. Z. Zhu, “Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time,” FEBS Letters, vol. 386, no. 2-3, pp. 243–246, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Ishida, D. L. Iden, and T. M. Allen, “A combinatorial approach to producing sterically stabilized (Stealth) immunoliposomal drugs,” FEBS Letters, vol. 460, no. 1, pp. 129–133, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Zalipsky, N. Mullah, J. A. Harding, J. Gittelman, L. Guo, and S. A. DeFrees, “Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains,” Bioconjugate Chemistry, vol. 8, no. 2, pp. 111–118, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Dagar, M. Sekosan, B. S. Lee, I. Rubinstein, and H. Önyüksel, “VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery,” Journal of Controlled Release, vol. 74, no. 1–3, pp. 129–134, 2001. View at Publisher · View at Google Scholar · View at Scopus